We are a global clinical-stage biopharmaceutical company focused on the development of innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.

Leveraging collaborations and internal discoveries, we have built a robust pipeline with strong potentials, including 11 drug candidates in development. Currently, four of them are being investigated in clinical trials, which are Buparlisib (AN2025), Pelareorep (AN1004), an oral EP4 antagonist (AN0025) and oral small-molecule PD-L1 inhibitor (AN4005).